08:22 AM EDT, 03/26/2026 (MT Newswires) -- Simulations Plus ( SLP ) said Thursday it is collaborating with three unnamed pharmaceutical companies to advance artificial intelligence workflows for drug development.

The company said the collaboration is intended to determine how AI can be integrated into real-world environments, including informing product direction, workflow standardization and future commercial models.

The programs will use the company's software platforms, including GastroPlus, MonolixSuite, ADMET Predictor, and Thales, Simulations Plus ( SLP ) said.